Cargando…

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours

AIMS: We investigated whether major gastrectomy influences the plasma exposure of regorafenib and treatment outcome. METHODS: Efficacy and pharmacokinetic data from 133 gastrointestinal stromal tumour patients included in a phase III trial were analysed. Patients were subdivided into 2 groups accord...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lubberman, Floor J.E., van der Graaf, Winette T.A., Xu, Lei, Cleton, Adriaan, Demetri, George D., Gelderblom, Hans, van Erp, Nielka P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783594/ https://www.ncbi.nlm.nih.gov/pubmed/31290566 http://dx.doi.org/10.1111/bcp.14061

Ejemplares similares

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)

Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
por: Giraud, Eline L., et al.
Publicado: (2023)

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
por: Schvartsman, Gustavo, et al.
Publicado: (2017)

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
por: Zuidema, Sander, et al.
Publicado: (2019)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
por: Nannini, Margherita, et al.
Publicado: (2017)

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022)

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake
por: Keunecke, Anne, et al.
Publicado: (2020)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry
por: IJzerman, Nikki S., et al.
Publicado: (2020)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
por: Khachatryan, Vahe, et al.
Publicado: (2022)

Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?
por: IJzerman, N.S., et al.
Publicado: (2022)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1 That Was Successfully Treated with Regorafenib
por: Fujimi, Akihito, et al.
Publicado: (2019)

Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study
por: Dirkson, Anne, et al.
Publicado: (2022)

New Systemic Therapy Options for Advanced Sarcomas
por: van der Graaf, Winette T. A., et al.
Publicado: (2012)

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
por: Gerisch, Michael, et al.
Publicado: (2017)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists
por: van de Wal, Deborah, et al.
Publicado: (2023)

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
por: Kollàr, Attila, et al.
Publicado: (2014)

Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre
por: Chamberlain, Florence, et al.
Publicado: (2020)

Gastrointestinal Stromal Tumours: An Update
por: Somerhausen, Nicolas De Saint Aubain, et al.
Publicado: (1998)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era
por: van der Graaf, W. T. A., et al.
Publicado: (2018)

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
por: Wong, Selina K., et al.
Publicado: (2019)

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
por: Wong, Andrea Li Ann, et al.
Publicado: (2015)

Gastrointestinal stromal tumour in Meckel's diverticulum
por: Chandramohan, K, et al.
Publicado: (2007)

The radiology of gastrointestinal stromal tumours (GIST)
por: Michael King, D
Publicado: (2005)

Primary mesenteric gastrointestinal stromal tumour
por: Kirby, R., et al.
Publicado: (2014)

Case of oesophageal gastrointestinal stromal tumour
por: Łochowska, Barbara, et al.
Publicado: (2017)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study
por: Nannini, M., et al.
Publicado: (2021)

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors
por: Boonstra, Pieter A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_48tuouck39kq2dus1emgd1p63g